Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$133.91 USD

133.91
402,043

+1.39 (1.05%)

Updated Apr 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries

Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.

Is Trending Stock DaVita Inc. (DVA) a Buy Now?

Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.

Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing

Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.

Reasons Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging

GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust

Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $126.11, representing a -1.2% change from its previous close.

Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis

Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.

Why You Should Add Inspire Medical (INSP) to Your Portfolio

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?

Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Philips (PHG) Agrees to a Consent Decree With DOJ and FDA

Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.